Visual Function in Prolactinoma Patients Treated with Bromocriptine

Mark L. Moster, Peter J. Savino, Norman J. Schatz, Peter J. Snyder, Robert C. Sergott, Thomas M. Bosley

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


Ten patients with prolactin-secreting pituitary adenomas (prolactinoma) and visual dysfunction were treated primarily with bromocriptine. Nine patients had improvement of visual field or acuity associated with computed tomography (CT) evidence of a decrease in tumor size and reduction of serum prolactin level (SPL). Visual improvement usually began within days of commencing bromocriptine therapy. One patient with initial improvement had a worsening of visual fields at 11 months despite a normal SPL and a stable CT appearance of tumor size. This patient and the single patient without visual improvement underwent trans-sphenoidal hypophysectomy (TSH), but neither patient had postoperative visual improvement. Two other patients underwent TSH for nonvisual reasons. The remaining six patients have maintained excellent visual function at last follow-up (average of 18 months on bromocriptine therapy). This study shows that bromocriptine is an effective short- and long-term therapy for most patients with visual dysfunction due to prolactinoma.

Original languageEnglish (US)
Pages (from-to)1332-1341
Number of pages10
Issue number10
StatePublished - 1985
Externally publishedYes


  • CSF rhinorrhea
  • bromocriptine
  • pituitary adenoma
  • prolactinoma
  • visual function

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Visual Function in Prolactinoma Patients Treated with Bromocriptine'. Together they form a unique fingerprint.

Cite this